ALZpath was founded in 2020 with the vision of improving the lives of those impacted by Alzheimer’s disease.
Our mission is to transform the Alzheimer’s disease ecosystem by innovating patient care, trials, and research through the integration of novel blood-based biomarkers, cognitive assessment tools, and care solutions.
We are a passionate, diverse, and focused group of medical researchers, healthcare professionals, and renowned scientific advisors dedicated to transforming the Alzheimer’s disease ecosystem through earlier diagnosis, intervention, and personalized treatment to improve outcomes for people with Alzheimer’s disease.
We understand the undue impact this disease places upon patients, families, caregivers, and the community at large. We are rooted in the belief that with a timely and accurate diagnosis, targeted treatment, education, and the appropriate care and support resources, it is possible for people to live well after an Alzheimer’s disease diagnosis. This is possible only by fundamentally rethinking, and rewriting the current diagnosis, treatment, and management paradigm.
Through our passion, creativity, and perseverance, we will rewrite the Alzheimer’s disease diagnosis, treatment, and management paradigm. We are steadfast in our commitment to improve the lives of those impacted by this disease.